While mutations in certain genes, such as BRAF, CALR, JAK2 and MPL, have diagnostic utility in myeloid neoplasms, for example, others such as CEBPA, DNMT3A, FLT3, IDH1, IDH2, KIT, NPM1, and TP53 have prognostic and/or therapeutic implications, particularly when determining whether a patient should undergo an allogeneic stem cell transplant1,2. This evidence concerns the gene TP53 and myeloid neoplasm.